- CEO
- Yong Zhu
- Full Time Employees
- 678
- Sector
- Process industries
- Industry
- Chemicals: major diversified
- Address
- Suzhou China
- IPO Date
- Jul 12, 2023
- Business
- Suzhou Highfine Biotech Co., Ltd. is a China-based biochemical synthesis and specialty chemical manufacturing company that develops, produces, and sells specialty reagents and advanced intermediates for the global pharmaceutical, biotechnology, and active pharmaceutical ingredient (API) industries. Founded in 2003 and headquartered in Suzhou, Jiangsu Province, China, the company operates across comprehensive chemical product segments and technical service offerings, including: peptide synthesis reagents, featuring uronium, phosphonium, and carbodiimide coupling reagents, condensation agents, racemization suppressants, and specialized protecting reagents; molecular building blocks and unnatural amino acids for medicinal chemistry and rational drug discovery; protein crosslinkers, chemical linkers, and functional payloads engineered for antibody-drug conjugates (ADCs); nucleotide synthesis reagents, phosphoramidites, and solid supports used in oligonucleotide therapeutics and mRNA technologies; proteolysis targeting chimera (PROTAC) building blocks and E3 ligase ligands; lipid excipients and lipid nanoparticle (LNP) reagents for targeted drug delivery platforms; ionic liquids and heterocyclic compounds; and custom development and manufacturing organization (CDMO) as well as contract research organization (CRO) services encompassing custom synthesis, chemical route scouting, process optimization, and commercial batch manufacturing. The company distributes its products to innovative pharmaceutical corporations, generic drug manufacturers, contract research organizations, and academic institutions across domestic China, North America, Europe, Japan, South Korea, and Southeast Asia. The company executes its manufacturing and research operations through key subsidiaries, including Anhui Highfine Biotech Co., Ltd., Huai'an Highfine Biotech Pharmaceutical Co., Ltd., and Hangzhou Foster Pharmaceutical Co., Ltd. In recent developments, the company listed its Class A shares on the ChiNext board of the Shenzhen Stock Exchange (SZSE:301393) to accelerate production and R&D infrastructure expansion. Suzhou Highfine Biotech completed the acquisition of an 85% equity stake in Hangzhou Foster Pharmaceutical Co., Ltd., integrating its GMP- and FDA-compliant production assets to broaden its regulated pharmaceutical manufacturing and fine chemical processing capabilities. Additionally, the company initiated construction on an approximately 1.8 billion RMB manufacturing base in Huai'an to deliver an annual capacity of 3,010 tons of peptide synthesis reagents, while also expanding its Anhui production base with 19 new product lines totaling 980 tons of specialized reagent capacity and commissioning its centralized corporate research and development headquarters in Suzhou.